Chip-based gene technology increasingly tying diagnostic, pharmaceutical development -- SB's Leschly.
This article was originally published in The Gray Sheet
Executive Summary
CHIP-BASED GENETIC TECHNOLOGY's LINKAGE OF DIAGNOSTIC AND DRUG DEVELOPMENT activities will become apparent over the next several years as commercial applications of genomics -- the study of gene location, structure and function -- are brought to bear through increased collaboration among the medical device, biotechnology and pharmaceutical industries, according to SmithKline Beecham Chief Executive Jan Leschly.